Day One Biopharmaceutical公司第四季度GAAP每股亏损$(0.69)未达预期$(0.36),销售额$29.21M超过预期$27.79M

财报速递2025-02-26
Day One Biopharmaceutical(NASDAQ:DAWN)报告其季度每股亏损$(0.69),未达到分析师预期的$(0.36),相差91.67%。相比去年同期,这一数值降低了7.81%,去年同期每股亏损$(0.64)。公司本季度报告销售额为$29.21百万,超过了分析师预期的$27.79百万,超出5.10%。

以上内容来自Benzinga Earnings专栏,原文如下:

Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.36) by 91.67 percent. This is a 7.81 percent decrease over losses of $(0.64) per share from the same period last year. The company reported quarterly sales of $29.21 million which beat the analyst consensus estimate of $27.79 million by 5.10 percent.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法